712 North

Operator of a pharmaceutical company aimed at spearheading personalized mitochondrial medicines for patients with complex diseases, such as Alzheimer’s dementia, heart failure, and cancer. The company’s approach merges mitochondria biology with pharmaceutical drug development by drugging the proteases of the mitochondrial inner membrane, thereby providing healthcare professionals with medicines for patients with complex diseases.